Your browser doesn't support javascript.
loading
Tamizaje nacional unificado de hipotiroidismo congénito en el Perú: un programa inexistente / National congenital hypothyroidism screening in Peru: a broken program
Huerta-Sáenz, Lina; Del Águila, Carlos; Espinoza, Oscar; Falen-Boggio, Juan; Mitre, Naim.
Affiliation
  • Huerta-Sáenz, Lina; Children's Mercy Hospital. Missouri. US
  • Del Águila, Carlos; Instituto Nacional de Salud del Niño. Servicio de Endocrinología Pediátrica. Lima. PE
  • Espinoza, Oscar; Instituto Nacional de Salud del Niño. Servicio de Endocrinología Pediátrica. Lima. PE
  • Falen-Boggio, Juan; Instituto Nacional de Salud del Niño. Servicio de Endocrinología Pediátrica. Lima. PE
  • Mitre, Naim; Children's Mercy Hospital. Missouri. US
Rev. peru. med. exp. salud publica ; 32(3): 579-585, jul.-sep. 2015.
Article in Es | LILACS, LIPECS, INS-PERU | ID: lil-790747
Responsible library: PE14.1
RESUMEN
El hipotiroidismo congénito (HC) es la principal causa prevenible de retardo mental. La prevalencia de HC varía de acuerdo con la región geográfica y la población racial. En el hemisferio norte, la incidencia es 14000 recién nacidos vivos. En Latinoamérica, la incidencia varía debido a la heterogeneidad racial/étnica y al nivel de desarrollo. En el Perú, un estudio realizado en 1984 describió esta prevalencia como 11250. En el 2007, esta prevalencia fue reportada como 11638 por el Instituto Nacional Materno Perinatal. Un reciente estudio del Instituto Nacional de Salud del Niño durante 1995û2005, describió la edad promedio de diagnóstico de HC como 5,9 meses +/- 5,28. Esta tardía edad de diagnóstico sugiere la poca eficiencia de los actuales programas de tamizaje. Todo niño peruano tiene derecho a recibir diagnóstico oportuno y tratamiento de HC y es el Estado Peruano, el responsable principal de asegurar que esta meta se cumpla...
ABSTRACT
Congenital hypothyroidism (CH) is the most important cause of preventable mental retardation. The prevalence of CH varies by geographic region, race and ethnicity. In the countries of the Northern hemisphere, the prevalence has been reported as 14,000 live newborns. The prevalence is remarkably different among the countries of Latin America not only because of their different races and ethnicities but also because of the heterogeneous social-economic development. The prevalence of CH in 1984 in Peru was reported as 11250. In 2007, the reported incidence by the Instituto Nacional Materno Perinatal was 11638. A recent retrospective study performed by the Instituto Nacional de Salud del Niño in Lima, Peru described the average age of diagnosis of CH as 5,9 months +/- 5,28. This late age of CH diagnosis certainly suggests the poor efficiency of the current neonatal CH screening programs in Peru. Every Peruvian infant deserves a timely newborn screening and treatment for CH. The Peruvian government is responsible for ensuring this mandatory goal is achieved promptly...
Subject(s)
Full text: 1 Collection: 01-internacional Database: INS-PERU / LILACS / LIPECS Main subject: Neonatal Screening / Congenital Hypothyroidism Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies / Screening_studies Limits: Humans Country/Region as subject: America do sul / Peru Language: Es Journal: Rev. peru. med. exp. salud publica Journal subject: SAUDE PUBLICA Year: 2015 Document type: Article Affiliation country: Peru / United States Country of publication: Peru
Full text: 1 Collection: 01-internacional Database: INS-PERU / LILACS / LIPECS Main subject: Neonatal Screening / Congenital Hypothyroidism Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies / Screening_studies Limits: Humans Country/Region as subject: America do sul / Peru Language: Es Journal: Rev. peru. med. exp. salud publica Journal subject: SAUDE PUBLICA Year: 2015 Document type: Article Affiliation country: Peru / United States Country of publication: Peru